Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Risk & Volatility
Pulse Biosciences has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Pulse Biosciences and ENDRA Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 1 | 0 | 2.00 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares Pulse Biosciences and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | N/A | -67.70% | -58.89% |
| ENDRA Life Sciences | N/A | -396.15% | -190.40% |
Insider & Institutional Ownership
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 74.6% of Pulse Biosciences shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Pulse Biosciences and ENDRA Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $700,000.00 | 1,327.32 | -$53.58 million | ($1.13) | -12.13 |
| ENDRA Life Sciences | N/A | N/A | -$11.51 million | ($26.45) | -0.22 |
ENDRA Life Sciences has lower revenue, but higher earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Pulse Biosciences beats ENDRA Life Sciences on 7 of the 10 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
